Details for Patent: 7,452,895

Which drugs does patent 7,452,895 protect, and when does it expire?

Patent 7,452,895 protects TUKYSA and is included in one NDA.

This patent has thirty-seven patent family members in twenty-six countries.

Summary for Patent: 7,452,895

Title:	Quinazoline analogs as receptor tyrosine kinase inhibitors
Abstract:	This invention provides quinazoline analogs of Formula I: ##STR00001## where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R.sup.3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Inventor(s):	Wallace; Eli (Lyons, CO), Topalov; George (Superior, CO), Lyssikatos; Joseph (Superior, CO), Buckmelter; Alexandre (Superior, CO), Zhao; Qian (Superior, CO)
Assignee:	Array BioPharma Inc. (Boulder, CO)
Application Number:	10/914,974
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 7,452,895

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No			Y	Y		TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-002	Apr 17, 2020		RX	Yes	Yes			Y	Y		TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER

International Family Members for US Patent 7,452,895

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	045378
Australia	2004264937
Brazil	PI0413565
Canada	2535614